Rare Kidney Diseases Treatment Market

Rare Kidney Diseases Treatment Market (Drug Class: Enzyme Replacement Therapy, Monoclonal Antibodies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Rare Kidney Diseases Treatment Market Outlook 2031

  • The global industry was valued at US$ 2.6 Bn in 2021
  • It is projected to grow at a CAGR of 5.8% from 2022 to 2031 and reach more than US$ 4.6 Bn by the end of 2031

Analysts’ Viewpoint

Incidence of acute renal failure and rare kidney diseases is rising significantly across the globe. Just a few treatment options have been approved for rare urinary diseases. New product launch and cost-effective treatments & services are likely to create lucrative opportunities for manufacturers in the global rare kidney diseases treatment market in the next few years, especially in developing countries.

Demand for rare kidney diseases treatment is rising across the globe, primarily in countries in Asia such as China and India, due to high incidence rate and need for effective kidney disease management. Leading players are focusing on developing new treatment options for rare kidney diseases.

Rare Kidney Diseases Treatment Market

Rare Kidney Diseases Treatment Market Introduction

Of the 150 different rare kidney diseases, majority are inherited. Each uncommon kidney disease has a unique set of symptoms; however, these rare diseases could collectively present overlapping diagnostic and therapeutic difficulties.

Small number of affected people, unknown disease causes, lack of biomarkers for diagnosis, and requirement of complex care are the key obstacles during diagnosis and treatment of these diseases. Rare kidney diseases are also known as rare urinary diseases. Rare kidney diseases include Fabry disease, atypical hemolytic uremic syndrome, lupus nephritis, nephropathic cystinosis, renal nutcracker syndrome, and others. Polycystic kidney disease (PKD) is a rare genetic kidney disease, in which clusters of cysts develop primarily within kidneys, resulting in an increase in size of the kidney.

Treatments for rare urinary diseases include enzyme replacement therapy, monoclonal antibodies, and others. Renal nutcracker syndrome is a rare vein compression disorder. It mostly affects left renal (kidney) vein. Symptoms of this disease include flank pain and blood in the urine. Increase in incidence of kidney diseases and rise in awareness among the people are the other factors driving market progress. Surge in geriatric population is likely to augment the global rare kidney diseases treatment market share in the near future.

Request a sample to get extensive insights into the Rare Kidney Diseases Treatment Market

Focus on New Product Development to Boost Rare Kidney Diseases Treatment Market Statistics

The burden of various rare kidney diseases is expected to rise significantly across the globe in the next few years. Kidney-related problems, such as Fabry disease, atypical hemolytic uremic syndrome, lupus nephritis, nephropathic cystinosis, renal nutcracker syndrome, polycystic kidney disease (PKD), distal renal tubular acidosis, and IgA nephropathy disease, have increased.

Several rare kidney diseases remain untreated, which could cause serious health issues in future. According to the World Health Organization, the Fabry disease is estimated to affect approximately 1 in 40,000 men and around 1 in 20,000 women in the U.S. As per the National Organization for Rare Disorders, Inc., the incidence rate of atypical hemolytic uremic syndrome is 2 individuals per 1 million among the general population in the country.

Major players are focusing on designing and developing new products for rare kidney diseases. For instance, Reata Pharmaceuticals has one innovative product, Bardoxolone methyl, in phase 3 for the treatment of polycystic kidney disease. Amicus Therapeutics has one product, Migalastat Monotherapy, in phase 3 for the treatment of the Fabry disease.

Strong Product Pipeline Fueling Enzyme Replacement Therapy Segment

In terms of drug class, the enzyme replacement therapy segment accounted for significant market share in 2021. Enzyme replacement therapy products are primarily used for the Fabry disease. These products include Galafold, Replagal, and Fabrazyme.

Increase in usage of enzyme replacement therapy in the treatment of the Fabry disease is likely to drive the segment during the forecast period. Strong enzyme replacement product pipeline is another major factor propelling the segment. Companies are focusing on launching enzyme replacement therapy products in untapped regions. This is likely to augment the segment in the near future.

Request a custom report on Rare Kidney Diseases Treatment Market

Increase in Treatment Options Bolstering Fabry Disease Segment

Based on indication, the Fabry disease segment is projected to account for major share of the industry during the forecast period. Rise in patient population with the Fabry disease and increase in usage of novel treatments, such as chaperone therapy, are driving the segment. Intensive R&D activities, strong product pipeline, and rise in usage of substrate reduction therapies & enzyme replacement therapies are likely to propel the segment.

Galafold, Replagal, and Fabrazyme are the products approved for Fabry disease treatment; more products in phase 3 are projected to be launched in the near future. Furthermore, surge in number of people diagnosed with the Fabry disease is anticipated to increase the demand for innovative treatment options.

Favorable Reimbursement Policies Driving Hospital Pharmacies Segment

In terms of distribution channel, the hospital pharmacies segment is likely to account for significant share during the forecast period. Preference for hospitals for the treatment of rare urinary diseases has increased due to favorable reimbursement policies. Therefore, the segment is anticipated to grow at a rapid pace during the forecast period.

Rise in awareness about rare kidney diseases & novel treatment options and the trend of utilization of new & improved drugs by patients and physicians are projected to propel the segment in the next few years.

Regional Outlook of Rare Kidney Diseases Treatment Industry

As per global rare kidney diseases treatment market forecast, North America accounted for the largest share of around 45% in 2021. The region's dominance can be ascribed to the increase in incidence rate of the Fabry disease, atypical hemolytic uremic syndrome, lupus nephritis, nephropathic cystinosis, and others kidney diseases. Increase in acceptance of technologically advanced products, surge in healthcare expenditure, early access to advanced technologies, and favorable funding by governments & charitable trusts for healthcare research are anticipated to accelerate market development in North America during the forecast period. The U.S. dominated the market in the region owing to factors such as presence of major players and increase in new product approvals from the U.S. FDA.

Asia Pacific is anticipated to be the fastest growing region for rare kidney diseases treatment during the forecast period. The region is anticipated to record significant market expansion from 2022 to 2031 due to large patient base in countries such as India and China and rise in awareness about rare urinary diseases.

Analysis of Key Players

The global rare kidney diseases treatment market is consolidated, with the presence of small number of leading players. Most of the companies are investing significantly in research & development, primarily to develop innovative rare kidney diseases treatment. Companies in business have adopted growth strategies such as expansion of product portfolio and mergers & acquisitions.

Calliditas Therapeutics AB, GSK plc., Aurinia Pharmaceuticals, Inc., Amicus Therapeutics, Inc., Shire (Takeda Pharmaceutical Company Limited), Sanofi, Advicenne, Alexion Pharmaceuticals, Inc., Horizon Therapeutics plc, Otsuka Pharmaceutical Co., Ltd. and Reata Pharmaceuticals, Inc. are the prominent players in the global rare kidney diseases treatment market.

Key Developments

  • In July 2022, Calliditas Therapeutics AB received marketing authorization from the European Commission (EC) for Kinpeygo for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults
  • In June 2022, Advicenne launched Sibnayal in the U.K. for the treatment of distal renal tubular acidosis
  • In January 2021, Aurinia Pharmaceuticals, Inc. received the U.S. FDA approval for LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis (LN), a condition that increases the risk of kidney failure, cardiac events, and death, and causes irreversible kidney damage

These players have been profiled in the market report based on parameters such as company overview, portfolio, segments, strategies, and recent developments.

Global Rare Kidney Diseases Treatment Market Snapshot

Attribute

Detail

Size in 2021

US$ 2.6 Bn

Forecast (Value) in 2031

More than US$ 4.6 Bn

Growth Rate

(CAGR)

5.8%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Drug Class
    • Enzyme Replacement Therapy
    • Monoclonal Antibodies
    • Others
  • Indication
    • Fabry Disease
    • Atypical Hemolytic Uremic Syndrome
    • Lupus Nephritis
    • Nephropathic Cystinosis
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Sales

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Calliditas Therapeutics AB
  • GSK plc
  • Aurinia Pharmaceuticals, Inc.
  • Amicus Therapeutics, Inc.
  • Shire (Takeda Pharmaceutical Company Limited)
  • Sanofi
  • Advicenne
  • Alexion Pharmaceuticals, Inc.
  • Horizon Therapeutics plc
  • Otsuka Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global rare kidney diseases treatment market in 2021?

The industry was valued at US$ 2.6 Bn in 2021.

How big will it be in 2031?

It is projected to reach more than US$ 4.6 Bn by 2031.

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 5.8% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Increase in incidence of rare kidney diseases and strong product pipeline.

Which region will account for major share during the forecast period?

North America is likely to account for major share from 2022 to 2031.

Who are the prominent players in the global rare kidney diseases treatment market?

Calliditas Therapeutics AB, GSK plc, Aurinia Pharmaceuticals, Inc., Amicus Therapeutics, Inc., Shire (Takeda Pharmaceutical Company Limited), Sanofi, Advicenne, Alexion Pharmaceuticals, Inc., Horizon Therapeutics plc, Otsuka Pharmaceutical Co., Ltd., and Reata Pharmaceuticals, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Rare Kidney Diseases Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Disease Epidemiology

        5.3. Key Industry Events

        5.4. COVID-19 Impact Analysis

    6. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Indication

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Indication, 2017–2031

            6.3.1. Fabry Disease

            6.3.2. Atypical Hemolytic Uremic Syndrome

            6.3.3. Lupus Nephritis

            6.3.4. Nephropathic Cystinosis

            6.3.5. Others

        6.4. Market Attractiveness Analysis, by Indication

    7. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Drug Class

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Drug Class, 2017–2031

            7.3.1. Enzyme Replacement Therapy

            7.3.2. Monoclonal Antibodies

            7.3.3. Others

        7.4. Market Attractiveness Analysis, by Drug Class

    8. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast, by Distribution Channel, 2017–2031

            8.3.1. Hospital Pharmacies

            8.3.2. Retail Pharmacies

            8.3.3. Online Sales

        8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Market Value Forecast, by Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness Analysis, by Region

    10. North America Rare Kidney Diseases Treatment Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Indication, 2017–2031

            10.2.1. Fabry Disease

            10.2.2. Atypical Hemolytic Uremic Syndrome

            10.2.3. Lupus Nephritis

            10.2.4. Nephropathic Cystinosis

            10.2.5. Others

        10.3. Market Value Forecast, by Drug Class, 2017–2031

            10.3.1. Enzyme Replacement Therapy

            10.3.2. Monoclonal Antibodies

            10.3.3. Others

        10.4. Market Value Forecast, by Distribution Channel, 2017–2031

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Sales

        10.5. Market Value Forecast, by Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Indication

            10.6.2. By Drug Class

            10.6.3. By Distribution Channel

            10.6.4. By Country

    11. Europe Rare Kidney Diseases Treatment Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Indication, 2017–2031

            11.2.1. Fabry Disease

            11.2.2. Atypical Hemolytic Uremic Syndrome

            11.2.3. Lupus Nephritis

            11.2.4. Nephropathic Cystinosis

            11.2.5. Others

        11.3. Market Value Forecast, by Drug Class, 2017–2031

            11.3.1. Enzyme Replacement Therapy

            11.3.2. Monoclonal Antibodies

            11.3.3. Others

        11.4. Market Value Forecast, by Distribution Channel, 2017–2031

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Sales

        11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Indication

            11.6.2. By Drug Class

            11.6.3. By Distribution Channel

            11.6.4. By Country/Sub-region

    12. Asia Pacific Rare Kidney Diseases Treatment Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Indication, 2017–2031

            12.2.1. Fabry Disease

            12.2.2. Atypical Hemolytic Uremic Syndrome

            12.2.3. Lupus Nephritis

            12.2.4. Nephropathic Cystinosis

            12.2.5. Others

        12.3. Market Value Forecast, by Drug Class, 2017–2031

            12.3.1. Enzyme Replacement Therapy

            12.3.2. Monoclonal Antibodies

            12.3.3. Others

        12.4. Market Value Forecast, by Distribution Channel, 2017–2031

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Sales

        12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific

        12.6. Market Attractiveness Analysis

            12.6.1. By Indication

            12.6.2. By Drug Class

            12.6.3. By Distribution Channel

            12.6.4. By Country/Sub-region

    13. Latin America Rare Kidney Diseases Treatment Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Indication, 2017–2031

            13.2.1. Fabry Disease

            13.2.2. Atypical Hemolytic Uremic Syndrome

            13.2.3. Lupus Nephritis

            13.2.4. Nephropathic Cystinosis

            13.2.5. Others

        13.3. Market Value Forecast, by Drug Class, 2017–2031

            13.3.1. Enzyme Replacement Therapy

            13.3.2. Monoclonal Antibodies

            13.3.3. Others

        13.4. Market Value Forecast, by Distribution Channel, 2017–2031

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Sales

        13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America

        13.6. Market Attractiveness Analysis

            13.6.1. By Indication

            13.6.2. By Drug Class

            13.6.3. By Distribution Channel

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Rare Kidney Diseases Treatment Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Indication, 2017–2031

            14.2.1. Fabry Disease

            14.2.2. Atypical Hemolytic Uremic Syndrome

            14.2.3. Lupus Nephritis

            14.2.4. Nephropathic Cystinosis

            14.2.5. Others

        14.3. Market Value Forecast, by Drug Class, 2017–2031

            14.3.1. Enzyme Replacement Therapy

            14.3.2. Monoclonal Antibodies

            14.3.3. Others

        14.4. Market Value Forecast, by Distribution Channel, 2017–2031

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Sales

        14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa

        14.6. Market Attractiveness Analysis

            14.6.1. By Indication

            14.6.2. By Drug Class

            14.6.3. By Distribution Channel

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by tier and size of companies)

        15.2. Market Share Analysis, by Company, 2021

        15.3. Company Profiles

            15.3.1. Calliditas Therapeutics AB

                15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.1.2. Product Overview

                15.3.1.3. Financial Overview

                15.3.1.4. Strategy Overview

                15.3.1.5. SWOT Analysis

            15.3.2. GSK plc

                15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.2.2. Product Overview

                15.3.2.3. Financial Overview

                15.3.2.4. Strategy Overview

                15.3.2.5. SWOT Analysis

            15.3.3. Aurinia Pharmaceuticals, Inc.

                15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.3.2. Product Overview

                15.3.3.3. Financial Overview

                15.3.3.4. Strategy Overview

                15.3.3.5. SWOT Analysis

            15.3.4. Amicus Therapeutics, Inc.

                15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.4.2. Product Overview

                15.3.4.3. Financial Overview

                15.3.4.4. Strategy Overview

                15.3.4.5. SWOT Analysis

            15.3.5. Shire (Takeda Pharmaceutical Company Limited)

                15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.5.2. Product Overview

                15.3.5.3. Financial Overview

                15.3.5.4. Strategy Overview

                15.3.5.5. SWOT Analysis

            15.3.6. Sanofi

                15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.6.2. Product Overview

                15.3.6.3. Financial Overview

                15.3.6.4. Strategy Overview

                15.3.6.5. SWOT Analysis

            15.3.7. Advicenne

                15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.7.2. Product Overview

                15.3.7.3. Financial Overview

                15.3.7.4. Strategy Overview

                15.3.7.5. SWOT Analysis

            15.3.8. Alexion Pharmaceuticals, Inc.

                15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.8.2. Product Overview

                15.3.8.3. Financial Overview

                15.3.8.4. Strategy Overview

                15.3.8.5. SWOT Analysis

            15.3.9. Horizon Therapeutics plc

                15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.9.2. Product Overview

                15.3.9.3. Financial Overview

                15.3.9.4. Strategy Overview

                15.3.9.5. SWOT Analysis

            15.3.10. Otsuka Pharmaceutical Co., Ltd.

                15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.10.2. Product Overview

                15.3.10.3. Financial Overview

                15.3.10.4. Strategy Overview

                15.3.10.5. SWOT Analysis

            15.3.11. Reata Pharmaceuticals, Inc.

                15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.3.11.2. Product Overview

                15.3.11.3. Financial Overview

                15.3.11.4. Strategy Overview

                15.3.11.5. SWOT Analysis

    List of Tables

    Table 01: Global Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 02: Global Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 03: Global Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 04: Global Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 05: North America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 06: North America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 07: North America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 08: North America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 09: Europe Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 11: Europe Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 12: Europe Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 13: Asia Pacific Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 15: Asia Pacific Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 16: Asia Pacific Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 17: Latin America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Country/Sun-region, 2017–2031

    Table 18: Latin America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 19: Latin America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 20: Latin America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 21: Middle east and Africa Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Country/Sun-region, 2017–2031

    Table 22: Middle east and Africa Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2031

    Table 23: Middle east and Africa Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

    Table 24: Middle east and Africa Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

    Table 25: Business Overview (Calliditas Therapeutics AB)

    Table 26: Business Overview (GSK plc)

    Table 27: Business Overview (Aurinia Pharmaceuticals, Inc.)

    Table 28: Business Overview (Amicus Therapeutics, Inc.)

    Table 29: Business Overview (Shire (Takeda Pharmaceutical Company Limited)

    Table 30: Business Overview (Sanofi)

    Table 31: Business Overview (Advicenne)

    Table 32: Business Overview (Alexion Pharmaceuticals, Inc.)

    Table 33: Business Overview (Horizon Therapeutics plc)

    Table 34: Business Overview (Otsuka Pharmaceutical Co., Ltd.)

    Table 35: Business Overview (Reata Pharmaceuticals, Inc.)

    List of Figures

    Figure 01: Global Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Rare Kidney Diseases Treatment Market Value Share, by Indication (2021)

    Figure 03: Global Rare Kidney Diseases Treatment Market Value Share, by Drug Class (2021)

    Figure 04: Global Rare Kidney Diseases Treatment Market Value Share, by Distribution Channel (2021)

    Figure 05: Global Rare Kidney Diseases Treatment Market Value Share, by Region (2021)

    Figure 06: Global Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 07: Global Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 08: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Fabry Disease, 2017–2031

    Figure 09: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Atypical Hemolytic Uremic Syndrome, 2017–2031

    Figure 10: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Lupus Nephritis, 2017–2031

    Figure 11: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Nephropathic Cystinosis, 2017–2031

    Figure 12: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 13: Global Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 14: Global Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 15: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Enzyme Replacement Therapy, 2017–2031

    Figure 16: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Monoclonal Antibodies, 2017–2031

    Figure 17: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 18: Global Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 19: Global Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 20: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031

    Figure 21: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031

    Figure 22: Global Rare Kidney Diseases Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031

    Figure 23: Global Rare Kidney Diseases Treatment Market Value Share Analysis, by Region, 2021 and 2031

    Figure 24: Global Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Region, 2022-2031

    Figure 25: North America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 26: North America Rare Kidney Diseases Treatment Market Value Share (%), by Country, 2021 and 2031

    Figure 27: North America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Country, 2022–2031

    Figure 28: North America Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 29: North America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 30: North America Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 31: North America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 32: North America Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 33: North America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 34: Europe Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 35: Europe Rare Kidney Diseases Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 36: Europe Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 37: Europe Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 38: Europe Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 39: Europe Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 40: Europe Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 41: Europe Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 42: Europe Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 43: Asia Pacific Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 44: Asia Pacific Rare Kidney Diseases Treatment Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 45: Asia Pacific Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 46: Asia Pacific Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 47: Asia Pacific Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 48: Asia Pacific Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 49: Asia Pacific Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 50: Asia Pacific Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 51: Asia Pacific Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 52: Latin America Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 53: Latin America Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 54: Latin America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 55: Latin America Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 56: Latin America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 57: Latin America Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 58: Latin America Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 59: Middle east and Africa Rare Kidney Diseases Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 60: Middle east and Africa Rare Kidney Diseases Treatment Market Value Share Analysis, by Indication, 2021 and 2031

    Figure 61: Middle east and Africa Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Indication, 2022–2031

    Figure 62: Middle east and Africa Rare Kidney Diseases Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031

    Figure 63: Middle east and Africa Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

    Figure 64: Middle east and Africa Rare Kidney Diseases Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031

    Figure 65: Middle east and Africa Rare Kidney Diseases Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

    Figure 66: Global Rare Kidney Diseases Treatment Market Share, by Company, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved